Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 9/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP12 | P39900 | 3/20 | 0.48 |
| ▸ | MMP14 | P50281 | 3/20 | 0.48 |
| ▸ | MMP15 | P51511 | 3/20 | 0.48 |
| ▸ | MMP16 | P51512 | 3/20 | 0.48 |
| ▸ | MMP26 | Q9NRE1 | 3/20 | 0.48 |
| ▸ | GHSR | Q92847 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095655 | 0.83 | HTR2A (0.56) | GRIN1GRIN2B | |
| SCHEMBL1095538 | 0.83 | ESR1 (0.65) | — | |
| SCHEMBL4937667 | 0.83 | ESR1 (0.65) | — | |
| SCHEMBL1095168 | 0.83 | ESR1 (0.52) | — | |
| SCHEMBL1095297 | 0.79 | ESR2 (0.60) | GRIN1GRIN2B | |
| SCHEMBL4932882 | 0.79 | ESR2 (0.60) | GRIN1GRIN2B | |
| SCHEMBL14282038 | 0.78 | ABHD6 (0.55) | — | |
| SCHEMBL5165131 | 0.78 | GRIN1 (0.54) | GRIN1GRIN2BHRH3MMP1MMP2 | |
| SCHEMBL5442726 | 0.77 | GHSR (0.51) | GRIN1GRIN2BHRH3GHSR | |
| SCHEMBL5442721 | 0.77 | GHSR (0.51) | GRIN1GRIN2BHRH3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | GRIN1 159/4885GRIN2B 33/4885HRH3 120/4885 |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | GRIN1 153/4885GRIN2B 32/4885HRH3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.